Clinical trials
Phase 2 Neoplasms, Glandular and Epithelial trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
22 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 6 |
| Completed | 5 |
| Terminated | 4 |
| Active, not recruiting | 3 |
| Not yet recruiting | 2 |
| Recruiting | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Assistance Publique - Hôpitaux de Paris | 2 |
| Catalysis SL | 2 |
| National Cancer Institute (NCI) | 2 |
| Xiaoxiang Chen | 2 |
| Belgian Gynaecological Oncology Group | 1 |
| Boston Scientific Corporation | 1 |
| Cedars-Sinai Medical Center | 1 |
| Dendreon | 1 |
| Heath Skinner | 1 |
| Neovii Biotech | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neoplasms, Glandular and Epithelial | 22 |
| Carcinoma | 17 |
| Neoplasms | 15 |
| Adenocarcinoma | 12 |
| Neoplasms by Histologic Type | 12 |
| Neoplasms by Site | 10 |
| Urogenital Neoplasms | 8 |
| Ovarian Neoplasms | 7 |
| Digestive System Neoplasms | 6 |
| Genital Neoplasms, Female | 6 |
Trials
Showing 26 to 22 of 22. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.